麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

中國(guó)生物制藥 Sino Biopharmaceutical
中國(guó)生物制藥有限公司于二零零零年二月二日在開(kāi)曼群島注冊(cè)成立之有限公司。本公司二零零零年九月二十九日在香港聯(lián)合交易所創(chuàng)業(yè)板上市并于二零零三年十二月八日成功轉(zhuǎn)至香港聯(lián)合交易所主板上市，股份代號(hào)為1177。

本集團(tuán)擁有優(yōu)秀的制藥企業(yè)管理和研發(fā)人才，擁有全國(guó)性的藥品銷售網(wǎng)絡(luò)，擁有一流的已通過(guò)中國(guó)國(guó)家藥品監(jiān)督局GMP認(rèn)證的：大容量注射劑、大容量注射劑(非PVC)、小容量注射劑、片劑、膠囊、顆粒劑、散劑等生產(chǎn)設(shè)施。

本集團(tuán)的宗旨是透過(guò)不斷開(kāi)發(fā)創(chuàng)新生物藥品及中藥現(xiàn)代制劑，為病人帶來(lái)健康，為股東創(chuàng)造價(jià)值。

本集團(tuán)產(chǎn)品主要醫(yī)療領(lǐng)域?yàn)楦尾　⑿哪X血管疾病、老年病等。本集團(tuán)也正在發(fā)展癌癥、鎮(zhèn)痛和呼吸道治療領(lǐng)域的藥物，以滿足市場(chǎng)和廣大的醫(yī)生及患者的需要。

本公司主要下屬公司為：
江蘇正大天晴制藥有限公司
北京泰德制藥有限公司
南京正大天晴制藥有限公司
江蘇正大豐海制藥有限公司
青島正大海爾制藥有限公司
江蘇正大清江制藥有限公司
正大邵陽(yáng)骨傷科醫(yī)院
上海通用藥業(yè)股份有限公司
北京正大綠洲醫(yī)藥科技有限公司
 

憑借本集團(tuán)多年來(lái)專注發(fā)展中國(guó)醫(yī)藥市場(chǎng)，尤以開(kāi)發(fā)獨(dú)家及專利藥為主，掌握市場(chǎng)信息之余亦具備完善的銷售網(wǎng)絡(luò)，已成為國(guó)內(nèi)重點(diǎn)醫(yī)藥企業(yè)之一。根據(jù)北京集琦醫(yī)藥網(wǎng)絡(luò)有限公司最新公布的二零零五年中國(guó)醫(yī)藥統(tǒng)計(jì)報(bào)表數(shù)據(jù)顯示，本集團(tuán)附屬公司江蘇正大天晴藥業(yè)股份公司（「江蘇正大天晴」）、共同控制公司北京泰德制藥有限公司（「北京泰德」）、長(zhǎng)期投資公司正大青春寶藥業(yè)有限公司（「正大青春寶」），按利潤(rùn)總額排名進(jìn)一步向前推進(jìn)，已擠身前五十強(qiáng)，可見(jiàn)本集團(tuán)超卓的盈利能力。

美國(guó)《福布斯》(Forbes)將本公司評(píng)為2005年亞太地區(qū)10億美元以下最佳公司之一。

Sino Biopharmaceutical Limited incorporated in the Cayman Islands with limited liability on 2 February, 2000. On 29 September 2000, the Company was listed on GEM of the Stock Exchange in Hong Kong and successfully commenced dealings in the Shares on the Main Board in Hong Kong on Dec 8, 2003 . Its ordinary shares are traded under the stock code 1177.

The Group has excellent talents specialized in management and R&D and a countrywide product sales network. The first-class production facilities for the volume injections, small volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines and granulated medicines, etc. have obtained the GMP certification from State Food and Drug Administration.

The Group's aims to bring healthier lives to people and greater value to its shareholders by developing innovative biopharmaceuticals and modernized Chinese medicines.

The Group produces medicines in two core therapeutic categories: cardio cerebral diseases and hepatitis. And it is extending development efforts to oncology, analgesic and respiratory medicines, in order to meet the increasing demands of medical practitioners and patients.

Main subsidiaries or jointly controlled entities:

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.

Beijing Tide Pharmaceutical Co., Ltd.

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Qingdao Chia Tai Haier Pharmaceutical Co., Ltd.

Jiangsu Chia Tai Qing Jiang Pharmaceutical Co., Ltd.

Chia Tai Shaoyang Orthopedic Hospital

Shanghai General Pharmaceutical Co., Ltd.

Beijing Chia Tai Green Continent Pharmaceutical Co., Ltd.

Being one of the most prominent pharmaceutical enterprises in the PRC, the Group's core competencies include its strategic focus on the Chinese pharmaceutical market, its abilities to develop exclusive proprietary drugs, to effectively collect market information, and to operate a comprehensive sales network. According to the Chinese Medicine Annual Report 2005 issued by Beijing JiQi, the Group's subsidiaries and its jointly-controlled entity, namely Jiangsu Chia Tai Tianqing Pharmaceutical Co. Ltd. (JCTT), Beijing Tide Pharmaceutical Co. Ltd. (Beijing Tide), and Chia Tai Qingchunbao Pharmaceutical Co. Ltd (the Group's long-term investment), all ranked amongst the top fifty enterprises in the industry in terms of profitability.

Forbes selected the Group as one of the Best 2005 Asian Companies Under A Billion.